In this context, a series of circulating physiological markers, including dehydroepiandrosterone sulfate (DHEAS), interleukin 6 (IL-6), C-reactive protein (CRP), cystatin C (Cyst-C), Alpha-2-macroglobulin (A2M), and soluble receptor for advanced glycation end-products (sRAGE), have been found to be associated with several age-related diseases and MM, indicating a potential clinical application for addressing patients with a higher risk of poor outcomes (31–34). This evidence concerns the gene A2M and Miyoshi myopathy.